The popularity of copyright’s blockbuster initially fueled a period of growth for pharma, however recent changes present a complicated outlook for shareholders. Lower-cost alternatives are eating into earnings, and https://dillanzfyq303754.blogoxo.com/41567605/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment